Lims will play a key role in the battle against the expanding crisis of multi-drug resistant tuberculosis as part of a comprehensive international initiative
Starlims has unveiled a joint effort with Lilly in the battle against the expanding crisis of multi-drug resistant tuberculosis (MDR-TB), a virulent mutated type of tuberculosis (TB) that is difficult to treat, and therefore much more likely to spread.
The Lilly MDR-TB partnership is a comprehensive initiative with the World Health Organisation (Who), the US Department of Health and Human Services Centers for Disease Control and Prevention (CDC), Brigham and Women's Hospital (BWH), an affiliate of Harvard Medical School, the International Council of Nurses (ICN), and Purdue University to increase the number of trained personnel and drugs available to treat the expanding crisis of MDR-TB.
Through funding from Lilly, the CDC has begun the implementation of Starlims as a platform for extensive laboratory-based electronic surveillance of patients resistance to drugs used for treating MDR-TB, in clinics throughout Russia and Kazakhstan.
Starlims is an enterprise level information system that brings together all public health laboratory activities into a single platform, offering comprehensive reporting, surveillance, and networking capabilities compatible with national and international standards.
Public health solutions from Starlims are designed as a platform for linking between regional public health partners working under the Phin framework, HL7 messaging protocols and using Loinc and Snomed as the common vocabulary for test names and observations.
This functionality enables cross site sample transfer and data exchange.
"The CDC and Starlims partnership allows us to apply Lims technology to monitor treatment effectiveness.
"This is a very critical component of our whole effort to address MDR-TB", stated Gail Cassell, vice president, scientific affairs and distinguished research scholar for infectious diseases, Eli Lilly.
"Starlims was honoured to be asked to join the CDC in the Lilly MDR-TB partnership that addresses one of today's most challenging public health threats" said Isaac Friedman, president and CEO of Starlims.
"Our specific role is to provide Starlims licenses and know-how necessary to implement an effective MDR-TB monitoring and surveillance infrastructure throughout a network of Who sponsored treatment centres".
